Resource Center

Explore our library of helpful resources and scientific content on GP-2250.

Resource Center Photo

Filter by Resource Type

  • All
  • Brochures
  • Publications
  • Videos

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Neuroendocrine carcinoma of the pancreas is a highly aggressive form of neu-roendocrine tumor associated with poor survival and increasing occurrence. GP-2250 is an emergent substance showing antineoplastic properties, especially in combination with Gemcitabine. This study was the first to evaluate the antineoplastic effects of GP-2250 on pancreatic neuroendocrine carcinoma.

Marie Buchholz , Johanna Strotmann, Britta Majchrzak-Stiller, Stephan Hahn 2 , Ilka Peters , Julian Horn Thomas Müller, Philipp Höhn, Waldemar Uhl and Chris Braumann


Mechanism of Action Explainer Video

While cancer therapies are becoming increasingly specific to tumor and mutation type, a tumor and mutation agnostic yet targeted agent is of high therapeutic utility. Learn about GP-2250’s unique mechanism of action, which kills cancer cells by disrupting their energy metabolism.

Method Of Action Explainer Video

New hope begins with novel science.

Panavance’s purpose is to give every patient the best possible chance to live a healthy and cancer-free life.

Panavance Novel Science Brochure

Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo

German Cancer Congress, February 2016, Berlin, Germany (Abstract: Oncology Res Treat 2016; 39 (supply 1):1–175, abstract ID 0144, DOI: 10.1159/000444354)

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, R.W. Pfirrmann, A.M. Chromik, W. Uhl.


Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.

2017, 17, 1-13. DOI: 10.1186/s12885-017-3204-x

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik.


Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer

ASCO Annual Meetings 2020, Chicago (Abstract: Journal of Clinical Oncology 38, no. 15_suppl. DOI: 10.1200/JCO.2020.38.15_suppl.e16750

C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.)


A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.

ASCO Gastrointestinal Cancers Symposium, Journal of Clinical Oncology 2022;40:4_suppl, TPS620-TPS620

A. Kasi, J. L. Iglesias.